- Home
- AMGN vs TXN Comparison
AMGN vs TXN Comparison
Compare AMGN & TXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- TXN
- Stock Information
- Founded
- AMGN 1980
- TXN 1930
- Country
- AMGN United States
- TXN United States
- Employees
- AMGN N/A
- TXN N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- TXN Semiconductors
- Sector
- AMGN Health Care
- TXN Technology
- Exchange
- AMGN Nasdaq
- TXN Nasdaq
- Market Cap
- AMGN 155.9B
- TXN 137.4B
- IPO Year
- AMGN N/A
- TXN N/A
- Fundamental
- Price
- AMGN $291.70
- TXN $197.27
- Analyst Decision
- AMGN Buy
- TXN Hold
- Analyst Count
- AMGN 21
- TXN 26
- Target Price
- AMGN $323.62
- TXN $194.62
- AVG Volume (30 Days)
- AMGN 2.5M
- TXN 6.3M
- Earning Date
- AMGN 08-05-2025
- TXN 07-22-2025
- Dividend Yield
- AMGN 3.29%
- TXN 2.74%
- EPS Growth
- AMGN 56.16
- TXN N/A
- EPS
- AMGN 10.94
- TXN 5.28
- Revenue
- AMGN $34,126,000,000.00
- TXN $16,049,000,000.00
- Revenue This Year
- AMGN $7.73
- TXN $11.94
- Revenue Next Year
- AMGN $1.69
- TXN $10.24
- P/E Ratio
- AMGN $26.47
- TXN $37.57
- Revenue Growth
- AMGN 15.56
- TXN N/A
- 52 Week Low
- AMGN $253.30
- TXN $139.95
- 52 Week High
- AMGN $346.85
- TXN $220.39
- Technical
- Relative Strength Index (RSI)
- AMGN 54.94
- TXN 64.71
- Support Level
- AMGN $286.60
- TXN $194.47
- Resistance Level
- AMGN $299.49
- TXN $200.62
- Average True Range (ATR)
- AMGN 5.47
- TXN 3.92
- MACD
- AMGN 0.21
- TXN -0.11
- Stochastic Oscillator
- AMGN 46.50
- TXN 84.36
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About TXN Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.